Quidel Corporation has announced that it will acquire Ortho Clinical Diagnostics in a transaction that is expected to close during the first half of fiscal year 2022, subject to customary closing conditions. The combined organization will unite technologies and platforms to provide customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings. Further, the combined company will aim to meet patient testing needs at all points of the care continuum, including reference labs, hospitals, physicians’ offices, urgent care centers and other locations.